Comparative Pharmacology
Head-to-head clinical analysis: BUTICAPS versus PENTOBARBITAL SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTICAPS versus PENTOBARBITAL SODIUM.
BUTICAPS vs PENTOBARBITAL SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butalbital, a barbiturate, acts as a GABA-A receptor agonist, enhancing inhibitory neurotransmission in the CNS; acetaminophen inhibits cyclooxygenase (COX) activity and modulates endogenous cannabinoid receptors; caffeine is a non-selective adenosine receptor antagonist.
Enhances gamma-aminobutyric acid (GABA) activity at GABA-A receptors, prolonging chloride channel opening and inhibiting neuronal firing.
500 mg orally every 8 hours.
Induction of anesthesia: 100-150 mg IV given over 30-60 seconds; additional increments of 25-50 mg as needed. Hypnotic/sedative: 100-300 mg IM or 150-200 mg PO at bedtime. Anticonvulsant in emergencies: 5-7 mg/kg IV slow push over 1-2 minutes, may repeat every 15-30 minutes up to a maximum of 1 g. Rectal administration: 120-200 mg as a single dose for sedation.
None Documented
None Documented
3-5 hours (prolonged in renal impairment; dose adjustment required for CrCl <30 mL/min)
Terminal elimination half-life of 20-30 hours in adults. In prolonged ICU sedation, context-sensitive half-life can extend significantly (up to 50-100 hours) due to redistribution and accumulation.
Renal (90% as unchanged drug), biliary/fecal (10%)
Primarily renal excretion of inactive metabolites (hepatic metabolism via CYP). Approximately 25-50% unchanged in urine at alkaline pH; biliary/fecal elimination minimal (<5%).
Category C
Category D/X
Barbiturate
Barbiturate